Theorem Clinical Research

Drug Sponsors

Daiichi Sankyo to acquire Ambit Biosciences for $410M

Monday, September 29, 2014 01:12 PM

Daiichi Sankyo, a Japan-based pharmaceutical, will acquire all outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer, followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

More... »


Cancer Core Europe consortium launches

Friday, September 26, 2014 03:15 PM

Cancer Core Europe—a consortium to address the cancer care/research continuum challenge, has launched. Its members are Gustave Roussy Cancer Campus Grand Paris; Cambridge Cancer Center, based in the U.K.; Karolinska Institute, of Stockholm, Sweden; the Netherlands Cancer InstituteVall d'Hebron Institute of Oncology (VHIO), of Barcelona, Spain; and the German Cancer Research Center (DKFZ) and its National Center for Tumor Diseases (NCT).

More... »


Bristol-Myers Squibb to build state-of-the-art campus in New Jersey

Thursday, September 25, 2014 12:52 PM

Bristol-Myers Squibb plans to build a 650,000-square-foot office building on company-owned land in Lawrenceville, N.J. Construction is expected to begin in the fall and the new facility is expected to open by the end of 2016.

More... »

Acorda Therapeutics to acquire Civitas Therapeutics

Thursday, September 25, 2014 12:48 PM

Acorda Therapeutics, a biotechnology company based in Ardsley, N.Y., has entered into an agreement to acquire Civitas Therapeutics, a Chelsea, Mass.-based, privately held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a phase III treatment candidate for OFF episodes of Parkinson’s disease (PD). The acquisition also includes rights to Civitas’ proprietary ARCUS pulmonary delivery technology and manufacturing facility with commercial-scale capabilities.

More... »

Shire to pay $56.5M to U.S. government

Thursday, September 25, 2014 12:43 PM

Shire has reached a final agreement with the U.S. Attorney’s Office to resolve a civil investigation of its sales and marketing practices for a period ending in 2010 relating to Adderall XR, Vyvanse, Daytrana, Lialda and Pentasa. Shire will pay $56.5 million, plus interest, fees and costs.

More... »

Cytori restructures, cuts third of work force

Wednesday, September 24, 2014 01:27 PM

Cytori Therapeutics, a San Diego-based developer of cell therapies based on autologous adipose-derived regenerative cells (ADRCs), plans to restructure its operations and reduce costs.

More... »

Avalon Ventures, GlaxoSmithKline launch two new companies

Tuesday, September 23, 2014 09:00 AM

Avalon Ventures has announced the launch of two new companies, Silarus Therapeutics and Thyritope Biosciences, formed through its collaboration with GlaxoSmithKline (GSK) to fund and launch up to 10 early-stage life science companies. Both companies will be located at COI Pharmaceuticals in San Diego, a community established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.

More... »

Study: Finding contributions and needs of life sciences industry in New Jersey

Monday, September 22, 2014 02:32 PM

Recognizing the continuing evolution of New Jersey’s life sciences industry, BioNJ has released a comprehensive report that documents the ongoing growth of the biotechnology sector in the state and combines and assesses the contributions of the entirety of the life sciences sector to New Jersey’s economy, including employment and economic impact.

More... »

Merck to acquire Sigma-Aldrich

Monday, September 22, 2014 02:31 PM

Merck has agreed to acquire Sigma-Aldrich, a St. Louis, Mo.-based life science and technology company, for $17 billion in an all-cash transaction.

More... »

Cubist opens international headquarters in Zurich

Monday, September 22, 2014 02:25 PM

Cubist Pharmaceuticals, a company focused on novel antibiotics, has announced the official opening of its international headquarters in Zurich, Switzerland. Located in a growing biopharmaceutical hub in Switzerland, the company's international operations complement its corporate headquarters in Lexington, Mass.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs